INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $18,622 | +37.5% | 260 | 0.0% | 0.00% | 0.0% |
| Q3 2023 | $13,544 | -17.7% | 260 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $16,464 | +16.9% | 260 | 0.0% | 0.00% | +50.0% |
| Q1 2023 | $14,079 | +20.9% | 260 | +18.2% | 0.00% | 0.0% |
| Q4 2022 | $11,642 | +16.4% | 220 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $10,000 | +150.0% | 220 | -56.0% | 0.00% | +100.0% |
| Q3 2019 | $4,000 | 0.0% | 500 | +150.0% | 0.00% | 0.0% |
| Q3 2018 | $4,000 | -33.3% | 200 | -42.9% | 0.00% | 0.0% |
| Q2 2018 | $6,000 | +200.0% | 350 | +321.7% | 0.00% | 0.0% |
| Q1 2018 | $2,000 | – | 83 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |